Primary CNS Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (07/27/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Primary Central Nervous System (CNS) Lymphoma

Added text to state that median overall survival (OS) in published trials generally ranges from 2 to 4 years, and that older age (>65 years) and HIV positivity are the most clinically relevant poor prognostic factors.

Treatment Option Overview for Primary CNS Lymphoma

Added text about a phase II study that identified 46 consecutive patients, most of whom received induction therapy with high-dose methotrexate, rituximab, and temozolomide, who underwent consolidation with high-dose thiotepa, busulfan, and cyclophosphamide followed by autologous stem cell transplant and no whole-brain radiation therapy; with a median follow-up of 30 months and a median age of 59 years, the 2-year progression-free survival was 92% and 2-year OS was 95%, with stable neurocognitive function (cited DeFilipp et al. as reference 37 and level of evidence 3iiiDiv).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Key References for Primary CNS Lymphoma Treatment

Next section >
About This PDQ Summary